NCT00665314View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

June 30, 2009

Conditions
LymphomaNon Hodgkin's LymphomaHodgkin's DiseaseMultiple Myeloma
Interventions
DRUG

Plerixafor (AMD3100)

0.24mg/kg SC for 2 to 7 days.

DRUG

Can be any registered nonpegylated form of G-CSF

10mcg/kg SC for 4 days followed by an additional 2 to 7 days.

Trial Locations (5)

Unknown

Berlin

Cologne

Dresden

Nuremberg

Würzburg

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00665314 - Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). | Biotech Hunter | Biotech Hunter